Evidence map›Paper›PMID 42196312›Full record

ArticleInternational journal of molecular sciences2026

HBV Envelope Protein-Bearing Vesicles Show Preferential Uptake in Hepatocyte-Derived Cells.

Eri Takayama, Misaki Enomoto, Manami Nagae, Momoko Tomoda, Yuta Miyazumi, Yuki Iwaisako, Ryota Shirasawa, Youichi Suzuki, Takashi Nakano, Keiji Ueda and 1 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Eri TakayamaDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Misaki EnomotoDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Manami NagaeDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Momoko TomodaDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Yuta MiyazumiDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.
Yuki IwaisakoDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.ORCID 0000-0003-0202-4009
Ryota ShirasawaAnalytical Technology Division, HORIBA Techno Service Co., Ltd., Kyoto 601-8305, Japan.
Youichi SuzukiDepartment of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.ORCID 0000-0003-3554-0755
Takashi NakanoDepartment of Microbiology and Infection Control, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
Keiji UedaDivision of Virology, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan.
Masahiro FujimuroDepartment of Cell Biology, Kyoto Pharmaceutical University, Kyoto 607-8412, Japan.ORCID 0000-0002-5165-0789

Funding

Smoking Research Foundation 2024G012TERUMO Life Science Foundation 24-Ⅲ3017The Science Research Promotion Fund N/A
6 · The paper itself

Abstract

Controlled delivery using nanoparticle-based systems has attracted considerable attention; however, achieving cell-type specificity remains a major challenge. To address this issue, we focused on the intrinsic cell tropism of viruses. The hepatocyte tropism of hepatitis B virus (HBV) is mediated by interactions between its large envelope protein (L protein) and host factors, including the sodium taurocholate cotransporting polypeptide (NTCP). In this study, we explored viral-like secretory vesicles (VLSVs) displaying HBV spike proteins as a virus-inspired vesicle platform for hepatocyte targeting. We previously established a method for producing VLSVs from HBV L- and S-expressing HEK293T cells. In the present study, we developed an improved protocol using exosome-depleted fetal calf serum and optimized ultracentrifugation, resulting in VLSVs with comparable particle numbers and sizes but approximately tenfold higher protein content per particle. VLSVs were concentrated using a two-layer sucrose cushion, labeled with DiI, and purified by sucrose density gradient ultracentrifugation. We evaluated DiI uptake in hepatocyte-derived cells (HepG2 and Huh7), non-hepatic cells (MDA-MB231, H1299, HeLa, and Vero), and NTCP-overexpressing HepG2 cells. VLSVs showed preferential uptake in the following order: NTCP-overexpressing HepG2 > HepG2 > Huh7 > non-hepatic cells. Furthermore, removal of the N-terminal Flag tag from the L protein enhanced hepatocyte-associated uptake, suggesting the importance of preserving the native structure of the preS1 domain. While vesicle characterization and mechanistic validation remain to be further investigated, these findings provide a proof-of-concept for a virus-inspired vesicle platform exhibiting preferential uptake in hepatocyte-derived cells.

Indexed as

Hepatitis B virusHepatocytesSecretory VesiclesViral Envelope ProteinsAnimalsHEK293 CellsHep G2 CellsHumansOrganic Anion Transporters, Sodium-DependentSymportersL protein, hepatitis B virusOrganic Anion Transporters, Sodium-Dependentsodium-bile acid cotransporterSymportersViral Envelope Proteinsdrug deliveryHBVhepatocytenanocarrierNTCPsecretory vesicleviral-like secretory vesiclevirus-like particle

Identifiers

PMID42196312
PMCPMC13207099

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.